A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer
- PMID: 36744321
- DOI: 10.1158/2159-8290.CD-22-1304
A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer
Abstract
The first KRASG12D inhibitor, MRTX113, leads to regression in multiple mouse models of PDAC as a monotherapy. MRTX113 blocks cancer cell proliferation, induces cancer cell death, and promotes immune infiltration and activation. See related article by Kemp et al., p. 298 (6).
©2023 American Association for Cancer Research.
Comment on
-
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Cancer Discov. 2023 Feb 6;13(2):298-311. doi: 10.1158/2159-8290.CD-22-1066. Cancer Discov. 2023. PMID: 36472553 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical